Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties
Guardant Health shares fell after a judge ruled against the company in a patent dispute and ordered it to pay royalties. The ruling adds a legal-cost and intellectual-property overhang to a business still growing revenue but reporting a -42.4% net margin.
The ruling follows a patent dispute involving Guardant Health, with the judge ordering royalties after finding against the company.
The direct exposure is GH, whose FY 2025 revenue was $982.0M, up 32.9% YoY, according to SEC EDGAR data. That growth sits alongside a -42.4% net margin and dilutive EPS of $-3.32, leaving the company financially sensitive to additional obligations.
Key questions include the size and duration of the royalty burden, any impact on product sales or licensing, and whether Guardant appeals the ruling. The market's initial reaction was negative, though the judgment's dollar value and whether operations are materially constrained remain unclear.
A judge ordered Guardant Health (GH) to pay royalties after ruling against the company in a patent dispute, adding a legal cost to a business reporting a -42.4% net margin.
The legal overhang matters most because GH is already operating at a -42.4% net margin with dilutive EPS of $-3.32, so an unspecified royalty obligation could further delay the path to profitability. Revenue growth of 32.9% YoY and FY 2025 revenue of $982.0M provide a fundamental offset, but the missing judgment amount prevents a larger directional target.
The trade is impaired if the royalty obligation is immaterial, the ruling is stayed or reversed on appeal, or the company discloses no meaningful impact to products and cash flow.
CoverageSource: Yahoo Finance · Published here MON, AUG 24 · 3:04 PM ET · 2 reports · 2 publishers in this record · latest listed: Investing.com · MON, AUG 24 · 3:04 PM ETHow this is decided →
STOCK PHOTO · DAVID GUERRERO- Investing.com — Guardant Health to appeal Delaware court ruling on patent case
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
GH's FY 2025 revenue grew 32.9% YoY to $982.0M, giving the company a tangible growth engine that could absorb a limited royalty burden.
The bear case is stronger on the disclosed facts: a patent loss with court-ordered royalties compounds GH's -42.4% net margin and dilutive EPS of $-3.32, while the amount owed remains unknown.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →